Current Gastroenterology Reports

, 16:378

Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Current State and Future Perspectives

  • Niels Vande Casteele
  • Brian G. Feagan
  • Ann Gils
  • Séverine Vermeire
  • Reena Khanna
  • William J. Sandborn
  • Barrett G. Levesque
Inflammatory Bowel Disease (S Hanauer, Section Editor)

DOI: 10.1007/s11894-014-0378-0

Cite this article as:
Vande Casteele, N., Feagan, B.G., Gils, A. et al. Curr Gastroenterol Rep (2014) 16: 378. doi:10.1007/s11894-014-0378-0
Part of the following topical collections:
  1. Topical Collection on Inflammatory Bowel Disease

Abstract

Current available anti-inflammatory drugs, in particular monoclonal antibodies directed against the cytokine tumor necrosis factor α (TNF), have greatly enhanced the treatment of inflammatory bowel diseases (IBD). Although many patients respond to ant-TNF therapy, a proportion of patients will not respond (primary non-response) or will lose response to the drug over time (secondary non-response). This loss of response can be caused by patient, TNF-inhibitor, or disease-related factors influencing the pharmacokinetics and pharmacodynamics of the drug. Therefore, monitoring pharmacological parameters (i.e. therapeutic drug monitoring) may help guide therapeutic decisions. This review emphasizes interesting and important new findings, and provides an updated overview, on the subject of therapeutic drug monitoring. While exploring the hypothesis that “one size does not fit all”, we focused on the first prospective studies investigating the novel approach in IBD of ‘target concentration adjusted dosing’ and personalized medicine.

Keywords

AdalimumabAnti-drug antibodiesAnti-TNFBiologicsCrohn’s diseaseImmunogenicityInfliximabTrough concentrationsUlcerative colitis

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Niels Vande Casteele
    • 1
    • 2
    • 3
  • Brian G. Feagan
    • 3
  • Ann Gils
    • 2
  • Séverine Vermeire
    • 4
  • Reena Khanna
    • 3
  • William J. Sandborn
    • 1
    • 3
  • Barrett G. Levesque
    • 1
    • 3
  1. 1.Division of GastroenterologyUniversity of California San DiegoLa JollaUSA
  2. 2.KU Leuven Department of Pharmaceutical and Pharmacological SciencesLaboratory for Therapeutic and Diagnostic AntibodiesLeuvenBelgium
  3. 3.Robarts Clinical TrialsWestern UniversityLondonCanada
  4. 4.Department of GastroenterologyUniversity Hospitals LeuvenLeuvenBelgium